In a major breakthrough for cancer care, the NHS in England has become the first health service globally to roll out a revolutionary “Trojan horse” therapy. Known as belantamab mafodotin—or Blenrep—the treatment is designed to sneak potent chemotherapy into multiple myeloma cells and unleash its deadly payload from the inside. Approval came from NICE on 12 June, and the very next day, NHS England confirmed it would be made available to around 1,500 patients annually whose cancer has returned or stopped responding to other treatments. As reported by The Guardian, this makes England the first country in the world to offer the treatment to eligible patients through a national health system.
Belantamab mafodotin is an antibody-drug conjugate developed in the UK by GlaxoSmithKline. It attaches to a specific protein called BCMA, found on the surface of myeloma cells. Once it binds, the drug enters the cell and delivers a chemotherapy agent that destroys it from within. It’s a precision-guided weapon designed to limit damage to healthy tissue while directly targeting the cancer. Clinical trials combining belantamab with bortezomib and dexamethasone found it delayed disease progression for around three years—far longer than the roughly one-year delay offered by the previous standard treatment involving daratumumab. The improvement isn’t just statistical—it translates into years of additional time with better quality of life for patients who previously had few options.
The news has been especially welcome for people like Paul Silvester, a 60-year-old from Sheffield, who accessed the drug through an early-access programme after his first line of treatment failed. Within weeks of his first infusion, Paul reported being in remission and said, “I feel like this treatment has brought the party balloons back in the house.” His experience offers real-world hope to patients and families who face the difficult path of relapsed or refractory myeloma. His story is now being held up by NHS England as an example of what this new drug can achieve.
Peter Johnson, NHS England’s national clinical director for cancer, described the development as a “life-changing” moment for patients. He noted that it gives families more time together and offers an advanced option for people who previously had limited or less effective treatments. NICE’s director of medicines evaluation, Helen Knight, added that the rollout reflects a commitment to speeding up access to high-impact treatments while ensuring value for the health system. She described it as a model of how fast-track approvals can change lives without compromising oversight.
The rollout of this treatment marks a wider shift in oncology toward personalised medicine.
It means using targeted therapies that are more effective and less harmful than traditional chemotherapy. Myeloma UK’s policy and public affairs director, Shelagh McKinlay, praised the NHS for leading the way and making innovative treatments available quickly. She said it shows that the UK is pushing boundaries in oncology, setting a high bar for access and research.
More than 6,000 people in the UK are diagnosed with multiple myeloma each year. While the condition is currently incurable, slowing its progression can add valuable years to patients’ lives and improve their day-to-day experience. Belantamab mafodotin, when combined with other drugs, gives a new avenue of hope for those with few options left. In addition to its therapeutic impact, the drug’s rollout comes with a practical infrastructure: patients will receive infusions every three weeks and undergo regular eye checks due to known ocular side effects. These routine checks ensure safety while allowing people to benefit from the drug’s targeted action.
It’s also worth noting that this treatment had a bumpy journey. While it was initially granted conditional approval in the United States, it was later withdrawn by the FDA after further trials didn’t meet expected benchmarks. But in the UK, regulators reviewed the newer data in context and opted to keep the therapy in circulation. The decision has been framed as an example of evidence-based pragmatism—using local expertise and ongoing research to make decisions that reflect both medical need and patient experience. In this case, a drug partly developed in Stevenage has gone on to make medical history within the very country that helped create it.
This isn’t just a medical milestone—it’s a sign of changing priorities in cancer care.
It shows that innovation isn’t limited to new molecules alone but also how they’re delivered, approved and made accessible. The NHS has taken a bold step, not just by offering belantamab mafodotin but by demonstrating that targeted therapy can be delivered quickly and equitably.
As more people begin to receive the treatment in the coming months, researchers and clinicians will gather real-world data to continue refining its use. It’s likely that this will inform how similar therapies are developed in the future—not just for myeloma, but potentially for other cancers that respond to targeted, antibody-based treatments. England’s early adoption of this “Trojan horse” approach may mark the start of a broader shift, one where precision, speed and patient outcomes define the new standard in cancer care.
What’s clear is that this drug represents much more than a clinical tool—it’s a symbol of what’s possible when innovation, regulation and patient need align. For those living with blood cancer, it’s a glimpse of a future where time, comfort and effectiveness aren’t mutually exclusive. And for health systems watching from afar, it’s a compelling example of how bold decisions can open doors to better, longer lives.